Liposomal encapsulated anti-cancer drugs

Anti-Cancer Drugs

Volumn 16, Issue 7, 2005, Pages 691-707

  Hofheinz, Ralf Dieter ^a   Gnad Vogt, Senta Ulrike ^a   Beyer, Ulrich ^b   Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MEDAC GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; INX 0076; INX 0125; IRINOTECAN; LIPOPLATIN; LIPOSOMAL ANTINEOPLASTIC AGENT; LIPOSOME; LURTOTECAN; MARQIBO; MBT 0206; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM 1,2 DIAMINOCYCLOHEXANE BISNEODECANOATE; RETINOIC ACID; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARACHNOIDITIS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HYPERSENSITIVITY; KAPOSI SARCOMA; LEUKEMIA; LEUKOPENIA; LIPID COMPOSITION; LIVER TOXICITY; LUNG SMALL CELL CANCER; LYMPHOMATOUS MENINGITIS; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARESTHESIA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSORY NEUROPATHY; SKIN IRRITATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARDIOMYOPATHIES; CLINICAL TRIALS; CYTARABINE; HUMANS; LIPOSOMES; NEOPLASMS; PLATINUM COMPOUNDS; VINCRISTINE;

EID: 23344439607     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000167902.53039.5a     Document Type: Review

References (125)

1. Bangham AD, Standish HM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13:238-252.
2. Sessa G, Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res 1968; 9:310-318.
3. Perez-Soler R. Liposomes as carriers of antitumor agents: towards a clinical reality. Cancer Treat Rev 1989; 16:67-82.
4. Martin FJ. Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology. Oncology 1997; 11(suppl 11):11-20.
5. Senior J, Gregoriadis G. Stability of small unilamellar liposomes in serum and clearance from the circulation: the effect of the phospholipid and cholesterol components. Life Sci 1982; 30:2123-2136.
6. Harrington KJ, Lewanski CR, Stewart JSW. Liposomes as vehicles for targeted therapy of cancer. Part 1 : preclinical development. Clin Oncol 2000; 12:2-15.
7. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumours. Pharmacol Rev 1999; 51:691-743.
8. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004; 31(suppl 13):16-35.
9. Yatvin MB, Kreutz W, Horwitz BA, Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 1980; 210:1253-1255.
10. Huang SK, Stauffer PR, Hong K, Guo JW, Philips TL, Huang A, et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994; 54:2186-2191.
11. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101:1401-1413.
12. Swain S, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. A retrospective analysis of three trials. Cancer 2003; 97:2869-2879.
13. Workman P. Infusional anthracyclines: is slower better? If so, why? Ann Oncol 1992; 3:591.
14. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 2004; 130:1-7.
15. Behringer DM, Engelhart R, Hofheinz RD, Hochhaus A, Herrmann R, Stern A, et al. A phase I dose escalation study on the tolerability and activity of BBR 3438 in patients with advanced solid tumours. Eur J Cancer 2002; 38(suppl):82P (abstr).
16. Hofheinz RD, Porta C, Hartung G, Santoro A, Hanauske AR, Kutz K, et al. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: a phase II study group trial of the Central European Society of Anticancer-drug Research (CESAR). Invest New Drugs 2005; in press.
17. Markman M, Gordon AN, McGuire WP, Muggia FM. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol 2004; 31 (suppl 13):91-105.
18. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
19. Gordon AN, Tonda M, Sun S, Rackoff W on behalf of the Doxil Study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95:1-8.
20. O'Byrne KJ, Bliss P, Graham JD, Gerber J, Vasey PA, Khanna S, et al. A phase III study of Doxil/Caelyx versus paclitaxel in platinum treated, taxane-naive relapsed ovarian cancer. Proc Am Soc Clin Oncol 2002; 21:808 (abstr).
21. Potamianou A, Polyzos A, Boukovinas J, Latoufis C, Andoulakis N, Agelidou S, et al. Sequential combination of paclitaxel, carboplatin and paclitaxel liposomal doxorubicin as 1st line treatment in patients with ovarian cancer: a multicenter phase II trial. Proc Am Soc Clin Oncol 2004; 23:5018 (abstr).
22. Ferrero JM, Weber B, Lepille D, Orfeuvre H, Combe M, Mayer F, et al. Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): survival results of a GINECO phase II trial. Proc Am Soc Clin Oncol 2004; 23:5022 (abstr).
23. Holloway RW, Finkler NJ, Nye LP, Bigsby GE, Ortiz BH. Doxil and gemcitabine combination therapy for recurrent ovarian cancer: results of a phase II trial. Proc Am Soc Clin Oncol 2004; 23:5090 (abstr).
24. Straughn JM, Rocconi RP, Leath CA, Kilgore LC, Huh WK, Alvarez RD. Feasibility study of liposomal doxorubicin consolidation therapy after platinum/paclitaxel based chemotherapy for suboptimally debulked stage IIIC/IV ovarian cancer patients. Proc Am Soc Clin Oncol 2004; 23:5044 (abstr).
25. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silveman P, et al. The role of liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol 2004; 31 (suppl 13):106-146.
26. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15:3185-3191.
27. Lyass O, Uziely B, Ben-Yosef R, Tzemch D, Heshing NI, Lotem M. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer. Cancer 2000; 89:1037-1047.
28. Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G, et al. Phase II study of single-agent pegylated liposomal doxorubicin HCL (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 2004; 27:441-446.
29. Keller AM, Mennel RG, Georgoulias V, Nabholtz JM, Erazo A, Lluch A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22:3893-3901.
30. O'Brien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCL (CAELYX™/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440-449.
31. Chia SK, Clemons M, Martin LA, Rodgers A, Gelmon K, Panasci L. A multicentre phase II trial of pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2004; 23:630 (abstr).
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 2001; 344:783-792.
33. Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23:1253-1260.
34. Krown SE, Northfelt DW, Osoba D, Stewart JS. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol 2004; 31(suppl 13):36-52.
35. Northfelt DW, Dezube BJ, Thommes JE, Levine R, von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15:653-659.
36. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International pegylated liposomal doxorubicin study group. J Clin Oncol 1998; 16:683-691.
37. Northfelt DW, Dezube BJ, Thommes JE, Miller BJ, Fischel MA, Friedmann-Kien A, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445-2451.
38. Mitsuyasu RT, van Roenn J, Krown S, Kaplan L, Testa M. Comparison study of liposomal doxorubicin (DOX) alone or with bleomycin and vincristine (DBV) for treatment of AIDS-related Kaposi's sarcoma (AIDS-KS): AIDS clinical trial group (ACTG) protocol 286. Proc Am Soc Clin Oncol 1997; 16:191 (abstr).
39. Hussein MA, Anderson KC. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol 2004; 31(suppl 13):147-160.
40. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31(suppl 13):36-52.
41. Harris L, Batist G, Belt R, Rovira D, Navari R, Azarnia N, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94:25-36.
42. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved anti-tumour efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19:1444-1454.
43. Chan S, Davidson N, Juozaityte E, Erdkamp F, Azarnia N, Lee LW on behalf of the myocet study group. Liposome-encapsulated doxorubicin (myocet) and cyclophosphamide is superior to epirubicin and cyclophosphamide in first-line therapy of metastatic breast cancer. Eur J Cancer 2001; 37(suppl 5):0-80 (abstr).
44. Trigo J, Climent MA, Lluch A, Gascon P, Hornedo J, Gil M, et al. Liposomal doxorubicin Myocet in combination with Herceptin and paclitaxel is active and well tolerated in patients with HER-2 positive locally advanced or metastatic breast cancer: a phase II study. Breast Cancer Res Treat 2003; 82(suppl 1):351 (abstr).
45. Theodoulou M, Campos SM, Batist G, Winer E, Norton L, Hudis C, et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002; 21:216 (abstr).
46. Forssen EA. The design and development of DaunoXome for solid tumor targeting in vivo. Adv Drug Deliv Rev 1997; 24:133-150.
47. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353-2364.
48. Martin F, Cooley T, Volberding P, Martin F, Tonda M, Kroll M. Final results of a phase III randomized trial of Doxil versus DaunoXome in patients with AIDS-related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 2002; 21:411 (abstr).
49. O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, Steward WP. A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer 2002; 87:15-20.
50. Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, et al. Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion. Anticancer Drugs 2003; 14:793-799.
51. Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, et al. Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 2001; 12:457-462.
52. Billingham M, Bristow M. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984; 3:71-76.
53. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In vivo 1993; 7:17-26.
54. Working PK, Newman MS, Sullivan T, Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J Pharmacol Exp Ther 1999; 289:1128-1133.
55. 2. Ann Oncol 2000; 11:1029-1033.
56. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10:1663-1682.
57. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor bearing mice. Cancer Chemother Pharmacol 1999; 43:1-7.
58. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, Working P. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999; 80:134-137.
59. Working PK, Newman MS, Sullivan T, Brunner M, Podell M, Zahenk Z, et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998; 46:155-165.
60. Veal GJ, Griffin MJ, Price E, Parry A, Dick GS, Little MA, et al. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-077, a liposome encapsulated formulation of cisplatin. Br J Cancer 2001; 84:1029-1035.
61. Meerum Terwogt JM, Groenewegen G, Pluim D, Maliepaard M, Tibben MM, Huisman A, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol 2002; 49:201-210.
62. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol 2001; 12:493-496.
63. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 2001; 23:427-432.
64. Sen A, Zhao Y, Zhang L, Hui SW. Enhanced transdermal transport by electroporation using anionic lipids. J Control Release 2002; 82:399-405.
65. Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 11:1-10.
66. Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res 2004; 24:2193-2200.
67. Stathopoulos GP, Boulikas T, Vougiouka M, Deliconstantinos G, Rigatos S, Darli E, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep 2005; 13:589-595.
68. Khoakhar AR, al-Baker S, Krakoff IH, Perez-Soler R. Toxicity and antitumour activity of cis-bis carboxylato(trans-R,R-1,2-diaminocyclohexane) platium (II) complexes entrapped in liposomes. Cancer Chemother Pharmacol 1989; 23:219-224.
69. Perez-Soler R, Khoakhar AR, Bernstein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato trans-R,R-1,2-diaminocyclohexane platinum-(II) entrapped in multilamellar vesicles. Cancer Res 1987; 47:6462-6466.
70. Perez-Soler R, Young LY, Drewinko B, Lautersztain J, Khoakar AR. Increased cytotoxicity and reversal of resistance to cisplatin with entrapment of cis-bis-neodecanoato trans-R,R-1,2-diaminocyclohexane platinum(II) in multilamellar vesicles. Cancer Res 1988; 48:4509-4512.
71. Perez-Soler R, Lopez-Berestein G, Lautersztain J, al-Baker S, Francis K, Macias-Kiger D, et al. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res 1990; 50:4254-4259.
72. Dragovich T, Mendelson D, Hoos A, Lewis J, Richardson, von Hoff D. A phase II trial of aroplatin (L-NDDP), a liposomal DACH platinum, in patients with metastatic colorectal cancer (CRC): a preliminary report. Proc Am Soc Clin Oncol Gastrointestinal Cancer Symp 2004; 260 (abstr).
73. Vadiei K, Siddik ZH, Khokhar AR, al-Baker S, Sampedro F, Perez-Soler R. Pharmacokinetics of liposome entrapped cis-bis-neodecanoato trans-R,R-1,2- diaminocyclohexane platinum (II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 1992; 30:365-369.
74. Perez-Soler R, Walsh GL, Swisher SG, Shin HJ, Kemp BL, Terry K, et al. Phase II study of liposome entrapped cisplatin-analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1999; 18:421 (abstr).
75. Bleyer WA. Intrathecal depot cytarabine therapy: a welcome addition to a limited armamentarium. Clin Cancer Res 1999; 5:3349-3351.
76. Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother 2000; 34:1173-1178.
77. Ye Q, Asherman J, Stevenson M, Brownson E, Katre NV. DepoFoam technology: a vehicle for controlled delivery of protein and peptide drugs. J Control Rel 2000; 64:155-166.
78. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984; 35:826-830.
79. Kim S, Chatelut E, Kim JC, Howell SB, Cates C, Kormanik PA, et al. Extended CSF cytarabine exposure following intrathecal administration of DTD 101. J Clin Oncol 1993; 11:2186-2193.
80. Glantz MJ, LaFollette S, Jaeckle K, Shapiro W, Swinnen L, Rozental J, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17:3110-3116.
81. Glantz MJ, Jaeckle KA, Chamberlain MA, Phuphanich S, Recht L, Swinnen LJ, et al. A randomized controlled trial comparing intrathecal sustained release cytarabine (DepoCyte) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumours. Clin Cancer Res 1999; 5:3394-3402.
82. Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabin. Br J Cancer 2001; 84:157-163.
83. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumour neoplastic meningitis. J Neuro-Oncol 2002; 57:231-239.
84. Langer CJ. Dilemmas in management: the controversial role of chemotherapy in PS 2 advanced NSCLC and the potential role of CT-2103 (Xyotax™). The Oncologist 2004; 9:398-405.
85. Singer JW, Shaffer S, Baker B, Bernareggi A, Stromatt S, Nierstedt D, Besman M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 2005; 16:243-254.
86. Soepenberg O, Sparreboom A, de Jonge MJA, Planting AST, de Heus G, Loos WJC, et al. Real-time pharmacokinetics guiding clinical decisions: phase 1 study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumors. Eur J Cancer 2004; 40:681-688.
87. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterisation of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Pharm Biopharm 2005; 59:177-187.
88. Ali S, Lei S, Pal A, Kamath N, Sarkar A, Sheikh S, et al. Enhanced anticancer effects of a novel liposome-based formulation of paclitaxel in human and murine tumour models in mice. Proc Am Assoc Cancer Res 2003; 44:1345 (abstr.)
89. Fishman MN, Elsayed YA, Damjanov N, Steinberg JL, Mahany JJ, Nieves JA, et al. Safety and tolerability of liposome entrapped paclitaxel (LEP-ETU) administered with and without premedication in patients with advanced cancer. Ann Oncol 2004; 15(suppl 3):402 (abstr).
90. Schmidt-Sody M, Strieth S, Krasnici S, Sauer B, Schulze B, Teifel M, et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9:2335-2341.
91. Strieth S, Eichhorn ME, Sauer B, Schulze B, Teifel M, Michaelis U, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110:117-124.
92. Griebel J, Eichhorn ME, Becker S, Werner A, Michaelis U, Ruhstorfer H, et al. Dynamische Magnetresonanztomographie zum Monitoring der Effektivität einer antivasculären Tumortherapie durch Paclitaxel enkapsuliert in kationische Lipidkomplexe. Röfo Fortsch Geh Röntgenstr 2004; 176(suppl 1):P164 (abstr).
93. Papyan A, Werner A, Ischenko I, Teifel M, Michaelis U, Jauch KW, et al. Combination of standard chemotherapy with MBT-0206 enhances the anti-tumor efficacy in a highly metastatic human pancreatic cancer mouse model. Presented at 121 Kongress der Deutschen Gesellschaft für Chirurgie, Berlin; 2004, available http://www.egms.de/en/meetings/dgch2004/04dgch235.shtml (accessed 18.03.2005).
94. Ridwelski K, Kettner E, Fahlke J, Bartelheim K, Hitzl M, Schulze B, et al. Phase I study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic or advanced unresectable gastrointestinal cancer (GI cancer). Proc Am Soc Clin Oncol 2004; 22:3163 (abstr).
95. Bartelheim K, Ognerubov A, Semiglazov VF, Vtoraya OM, Kaletta C, Reichenberger I, et al. Phase Ib study of the anti-neovascular agent MBT-0206 to evaluate safety and efficacy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 22:3079 (abstr).
96. Gerrits CJ, Creemers GJ, Scheelens JHM, Wissel P, Planting AS, Kunka R, et al. Phase I and pharmacological study of the new topoisomerase inhibitor GI147211 using a daily × 5 intravenous administration. Br J Cancer 1996; 73:744-750.
97. Pratesi G, Beretta GL, Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 2004; 15:545-552.
98. Sadzuka Y, Hirotsu S, Hirota S. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res 1999; 90:226-232.
99. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, Harasym N, et al. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 2004; 10:6638-6649.
100. Zhang JA, Xuan T, Parmar M, Ma L, Ugwu S, Ali S, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 2004; 270:93-107.
101. Chien PY, Sheikh S, Zhang A, Ali S, Ahmad I. Cytotoxicity evaluation of a liposome-based formulation of SN38 in human and murine cancer cell lines. Proc Am Ass Cancer Res 2003; 44:1607 (abstr).
102. Kamath N, Sarkar AK, Sheikh S, Zhang A, Ali S, Ahmad I. Therapeutic efficacy of liposome-based formulation of SN38 against leukemia model in CD2F1 mice. Proc Am Ass Cancer Res 2003; 44:1784 (abstr).
103. Fishman M, LoRusso P, Kraut E, Fleming C, Paulson S, Steinberg J, et al. Phase I study of liposome encapsulated SN38 (LE-SN38) in patients with advanced cancer. Proc Am Soc Clin Oncol 2003; 22: (abstr).
104. Wanders J, van Oosterom AT, Gore M, Calvert HA, Ten-Bokkel Huinink WA, Hansen HH, et al. A phase II study with GI147211 in ovarian cancer. Eur J Cancer 1997; 33(suppl):118 (abstr).
105. Wanders J, Dombernowsky P, Nielsen D, Morant R, Drings P, Sessa C, et al. A phase II study with GI147211 (GW211) in small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17:1823 (abstr).
106. Emerson DL, Bendele R, Brown E, SuMing C, Desjardins JP, Dihel LC, et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin Cancer Res 2000; 6:2903-2912.
107. Loos WJ, Verweij J, Kehrer DFS, de Bruijn P, de Groot FMH, Hamilton M, et al. Structural identification and biological activity of 7-methyl-10,11- ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan. Clin Cancer Res 2002; 8:856-862.
108. Giles FJ, Taliman MS, Garcia-Manero G, Cortes JE, Thomas DA, Wierda WG, et al. Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 2004; 100:1449-1458.
109. Gelmon K, Hirte H, Fisher B, Walsh W, Ptaszynski M, Hamilton M, et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancer. Inv New Drugs 2004; 22:263-275.
110. Kehrer DFS, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, et al. Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity. J Clin Oncol 2002; 20:1222-1231.
111. Duffaud F, Borner M, Chollet P, Vermorken JB, Bloch J, Degardin M, et al. Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC early drug development group study. Eur J Cancer 2004; 40:2748-2752.
112. Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, Leray JD, Brown EN, et al. Biodistribution of OSI-211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs 2001; 12:235-245.
113. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, et al. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004; 93:229-232.
114. Dark GG, Calvert AH, Grimshaw R, Poole C, Swenerton K, Kaye S, et al. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2005; 23:1859-1866.
115. Boman NL, Bally BB, Cullis PR. Encapsulation of vincristine in liposomes reduces its toxicity and improves its antitumor efficacy. J Liposome Res 1995; 5:523-541.
116. Kanter PM, Klaich GM, Bullard GA, Pilkiewicz FG, Mayer LD, Culiis PR, et al. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 1994; 5:579-590.
117. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, et al. Phase I study of liposomal vincristine. J Clin Oncol 1999; 17:697-705.
118. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000; 11:69-72.
119. Rodrigues MA, Sarris A, East K, Dang NH, Fayad L, Goy A, et al. A phase II study of liposomal vincristine in CHOP with rituximab for elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 2004; 20:1132 (abstr).
120. Bennett CL, Caljoun EA. Pharmacoeconomics of liposomal anthracycline therapy. Semin Oncol 2004; 31(suppl 13):191-195.
121. Moeremans K, Annemans L, Morris JD. Liposomal cytarabine (DepoCyte™ injection) is cost-effective compared with standard cytarabine for the intrathecal treatment of patients with lymphomatous meningitis. Blood 2004; 104(suppl):267 (abstr).
122. Mamot C, Drummond DC, Greisser U, Hong K, Kirpotin DB, Marks JD, et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003; 63:3154-3161.
123. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31(suppl 13):196-205.
124. Swenson CE, Perkins WR, Roberts O, Janoff AS. Liposome technology and the development of Myocet (liposomal doxorubicin citrate). The Breast 2001; 10(suppl 2):1-7.
125. Richly H, Oberhoff C, Strumberg D, Grubert M, Kredtke S, Hartlapp J, et al. Pharmacokinetics (PK) of the liposomal encapsulated fraction (Caelyx, Doxil) as well as released doxorubicin after intravenous infusion of pegylated liposomes: PK based evidence for an indirect tumor targeting and a high systemic disposition of the released drug. Proc Am Soc Clin Oncol 2002; 32:478 (abstr).